Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.

Johnson EE, Buhtoiarov IN, Baldeshwiler MJ, Felder MA, Van Rooijen N, Sondel PM, Rakhmilevich AL.

J Immunother. 2011 Jan;34(1):76-84. doi: 10.1097/CJI.0b013e318200b28a.

2.

In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.

Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL.

J Leukoc Biol. 2006 Jun;79(6):1181-92. Epub 2006 Mar 24.

PMID:
16565324
3.

CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.

Hiramatsu K, Serada S, Kobiyama K, Nakagawa S, Morimoto A, Matsuzaki S, Ueda Y, Fujimoto M, Yoshino K, Ishii KJ, Enomoto T, Kimura T, Naka T.

Cancer Sci. 2015 Oct;106(10):1474-8. doi: 10.1111/cas.12738.

4.

Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL.

Int Immunopharmacol. 2013 Dec;17(4):1141-7. doi: 10.1016/j.intimp.2013.10.019. Epub 2013 Nov 4.

5.

CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.

Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL.

J Immunol. 2005 May 15;174(10):6013-22.

6.

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Alderson KL, Luangrath M, Elsenheimer MM, Gillies SD, Navid F, Rakhmilevich AL, Sondel PM.

Cancer Immunol Immunother. 2013 Apr;62(4):665-75. doi: 10.1007/s00262-012-1372-8. Epub 2012 Nov 15.

7.

Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL.

J Immunother. 2013 Jan;36(1):29-40. doi: 10.1097/CJI.0b013e3182780f61.

8.

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL.

Immunology. 2011 Feb;132(2):226-39. doi: 10.1111/j.1365-2567.2010.03357.x. Epub 2010 Oct 13.

9.

CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.

Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, Sondel PM.

Cancer Immunol Immunother. 2008 Aug;57(8):1151-60. doi: 10.1007/s00262-007-0447-4. Epub 2008 Jan 24.

PMID:
18214476
10.

Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.

Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL.

Immunology. 2007 Mar;120(3):412-23. Epub 2006 Dec 8.

11.

Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.

Shi Y, Felder MA, Sondel PM, Rakhmilevich AL.

Mol Immunol. 2015 Aug;66(2):208-15. doi: 10.1016/j.molimm.2015.03.008. Epub 2015 Mar 28.

12.

Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.

Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL.

J Immunol. 2006 Jan 1;176(1):309-18.

13.

Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.

Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizée G, Zhou D, Overwijk WW, Hwu P.

J Immunother. 2012 Apr;35(3):276-82. doi: 10.1097/CJI.0b013e31824e7f43.

14.

Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.

Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J.

Immunol Cell Biol. 2008 Aug-Sep;86(6):506-14. doi: 10.1038/icb.2008.27. Epub 2008 Apr 8.

PMID:
18392040
15.

Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.

Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H.

J Immunol. 2001 Jan 1;166(1):89-94.

17.

Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.

Chen W, Yu Y, Shao C, Zhang M, Wang W, Zhang L, Cao X.

Immunol Lett. 2001 May 1;77(1):17-23.

PMID:
11348665
18.

T-cell-independent antitumor effects of CD40 ligation.

Rakhmilevich AL, Alderson KL, Sondel PM.

Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337. Review.

19.
20.

A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.

Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5756-60.

Supplemental Content

Support Center